MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"),a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Ursula Ungaro will be joining its Board of Directors as of June 1, 2021.
Ms. Ungaro was appointed to serve on the federal U.S. District Court for the Southern District of Florida in 1992 after being nominated by President George H.W. Bush and being confirmed by the U.S. Senate. After 29 years of federal service, Ms. Ungaro has announced that she will be retiring from the bench on May 31, 2021. In her time on the federal bench, she presided over and ruled in numerous major civil and criminal cases in legal domains ranging from constitutional principles, equal rights, securities issues, and the use of non-embryonic stem cell therapies, amongst many others. In addition to joining Longeverons Board, Ms. Ungaro will also be joining, as a Partner, the prestigious law firm Boies Schiller Flexner LLP.
We are exceptionally fortunate and pleased to welcome Ms. Ungaro to our Board of Directors and look forward to drawing from her varied expertise after many years in the judiciary and in private practice to help guide Longeveron at this exciting time in its development, said Geoff Green, CEO of Longeveron. Ms. Ungaros tremendous reputation, respect of all her peers, and wealth of experience, will prove invaluable as we continue to build Longeveron and advance our cellular therapies through clinical development to commercialization.
Following her graduation with honors from the University of Florida School of Law in 1975 (one of just 17 women in a class of about 250), Ms. Ungaro practiced law in Miami, Florida where in 1981 she became a partner in Tew, Critchlow, Sonberg, Traum & Friedbauer, P.A. (later merged into Finley, Kumble, Wagner, Heine, Underberg, Manley, Myerson & Casey, a national law firm). She subsequently joined Sparber, Shevin, Shapo & Heilbronner, a prestigious local law firm. She practiced law mainly in the area of complex commercial litigation, including in the areas of securities, corporate and tax law. From 1987 to 1992, Ms. Ungaro served as a trial judge on the Eleventh Judicial Circuit of the State of Florida. She has authored published articles in the areas of administrative law, legal ethics, and civil procedure. She is the recipient of the ORT Jurisprudence Award and has been recognized on several occasions by other organizations for her achievements in the law and service to the community.
I am excited to have the opportunity to serve on the Board and to have the chance to participate with some very talented individuals in guiding Longeverons future success. In fact, a big part of my decision to retire from the judiciary was the opportunity to propel the further growth and success of Longeveron and help advance the exciting cell-based therapeutics the Company is developing, remarked Judge Ungaro.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Companys lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Companys mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at http://www.longeveron.com.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements that reflect management's current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as "believe," "expects," "may," "looks to," "will," "should," "plan," "intend," "on condition," "target," "see," "potential," "estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Moreover, forward-looking statements in this release include, but are not limited to, statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials; the size of the market opportunity for our product candidates, the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates, our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:
Brendan PayneStern Investor RelationsOffice Direct: 212-698-8695 |Office Main: 212-362-1200brendan.payne@sternir.com | http://www.sternir.com
Source: Longeveron IncSource: LGVN
Read more:
Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors - GlobeNewswire
- Parental Fury After Stem Cell Bank Ruins Thousands of Samples in Singapore - Bloomberg - April 24th, 2024
- Pressure in the womb may influence facial development - Phys.org - April 24th, 2024
- Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis - Nature.com - April 24th, 2024
- Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platform - FiercePharma - April 19th, 2024
- The Stem Cells Market expected to grow at the value of USD 28.1 Billion by 2030 with a 10.48% CAGR. - WhaTech - April 19th, 2024
- Scientists produce in vitro model of cell differentiation during early facial development - Phys.org - April 19th, 2024
- Somite: AI-Based Stem Cell Therapy Company Closes $5.3 Million In Funding - Pulse 2.0 - April 19th, 2024
- Paralyzed man who can walk again shows potential benefit of stem cell therapy - ABC News - April 5th, 2024
- Stem Cells Market Innovations Investigated by Industry Overview and Global Forecast - WhaTech - April 5th, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - University of Wisconsin-Madison - April 1st, 2024
- The PTM profiling of CTCF reveals the regulation of 3D chromatin structure by O-GlcNAcylation - Nature.com - April 1st, 2024
- Signatures of Autofluorescence Used To Study Stem Cells Aging in the Brain - Technology Networks - March 30th, 2024
- Two decades of embryonic stem cells: a historical overview - March 28th, 2024
- Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats - The Malaysian Reserve - March 26th, 2024
- Unlocking the mysteries of early human development through blastoid models - News-Medical.Net - March 24th, 2024
- Unlocking the Secrets of Aging: Researchers Reveal Key to Intestinal Balance - SciTechDaily - March 17th, 2024
- Human stem-cell-based therapy for Parkinson's disease proven safe PET - BioNews - March 13th, 2024
- Exploring the inner workings of stem cells: When location changes the message - Phys.org - March 9th, 2024
- Confronting IVF: Human Embryos Are Persons With a Right to Life - Walter Bradley Center for Natural and Artificial Intelligence - March 7th, 2024
- When Location Changes the Message - UConn Today - University of Connecticut - March 7th, 2024
- Distinct pathways drive anterior hypoblast specification in the implanting human embryo - Nature.com - March 6th, 2024
- In light of the Alabama court ruling, a look at the science of IVF : Short Wave - NPR - March 3rd, 2024
- The weird way Alabamas embryo ruling takes on artificial wombs - MIT Technology Review - February 25th, 2024
- Alabama's biggest hospital to suspend transfer of embryos after court ruling - ABC News - February 24th, 2024
- Stem Cells: FAQs Answered for Patients and Caregivers - Corporate Wellness Magazine - February 22nd, 2024
- Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells - Business Wire - February 22nd, 2024
- Breakthrough Stem Cell Treatments for Stroke Recovery: What You Need to Know - Medical Tourism Magazine - February 20th, 2024
- Global Cell Isolation Market Size To Worth USD 13.4 Billion By 2033 | CAGR of 12.5% - Yahoo Finance - February 20th, 2024
- The Mechanism of Positional Cues in Embryonic Development and Signaling Molecules in Cell Fate - Medriva - February 18th, 2024
- Regeneration of the Retina Using Pluripotent Stem Cells: A Comprehensive Review - Cureus - February 5th, 2024
- CRISPR/Cas9-mediated deletion of a GA-repeat in human GPM6B leads to disruption of neural cell differentiation from ... - Nature.com - January 29th, 2024
- Global Human Embryonic Stem Cell Market Analysis 2024-2034: A Deep Dive into Applications, End-users, and ... - GlobeNewswire - January 26th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - Yahoo News - January 14th, 2024
- Clinical applications of stem cell-derived exosomes | Signal Transduction and Targeted Therapy - Nature.com - January 12th, 2024
- How Stem Cell Embryo Models Won Method of the Year - Technology Networks - January 12th, 2024
- Changing the public perception of human embryology - ESHRE - January 11th, 2024
- How the Human Body Regenerates New Cells Every Year - Laughing Squid - January 4th, 2024
- Lab-grown models of embryos increasingly resemble the real thing | Mint - Mint - January 4th, 2024
- Singapore should ban reproductive applications of synthetic human embryos - BioEdge - January 4th, 2024
- Machine learning-based estimation of spatial gene expression pattern during ESC-derived retinal organoid ... - Nature.com - December 21st, 2023
- The development of embryos may be less shaped by genes than we thought - New Scientist - December 21st, 2023
- Embryonic stem cell - Wikipedia - December 13th, 2023
- Researchers discover a mechanism that controls the identity of stem cells - Phys.org - December 9th, 2023
- 'Fascinating and completely unexpected': Tiny robots fix neurons - FierceBiotech - December 5th, 2023
- Establishment and characterization of matched immortalized human ... - Nature.com - December 5th, 2023
- Proteomic insights into the associations between obesity, lifestyle ... - BMC Medicine - December 5th, 2023
- New therapy can treat rare and hereditary diseases - ScienceNorway - December 5th, 2023
- Scientists Still Can't Be Trusted on Gene Editing - Progressive.org - December 5th, 2023
- Harvard Apparatus Regenerative Technology and Renowned ... - Yahoo Finance - December 5th, 2023
- 4.4 Million Funding Injection Fuels World-Class Bioscience Research Programme - India Education Diary - December 3rd, 2023
- A two-kinesin mechanism controls neurogenesis in the developing ... - Nature.com - December 3rd, 2023
- What happens when nature and cities collide - CNN - December 3rd, 2023
- Pro-Life This Week: December 1, 2023 | ALL - All.org - December 3rd, 2023
- A look at the international race to create human eggs and sperm in ... - NPR - December 1st, 2023
- Synthetic genetic circuits to uncover the OCT4 trajectories of ... - Science - December 1st, 2023
- Why the Novo Nordisk Foundation is betting big on stem cells - pharmaphorum - November 29th, 2023
- Charity Watchlist Helps Donors Ensure Their Year-End Gifts Don't ... - All.org - November 29th, 2023
- A green glowing monkey has been created in China. What were the ... - Genetic Literacy Project - November 29th, 2023
- Fetal Bovine Serum Market to reach USD 1.26 Bn by 2029, emerging at a CAGR of 5.3 percent according to a ne... - WhaTech Technology and Markets News - November 29th, 2023
- Implications of Gene Therapy in Dentistry and Periodontics: A ... - Cureus - November 27th, 2023
- Study shows how to treat hereditary, rare diseases - ETHealthWorld - November 27th, 2023
- Drugs identified that may reverse brain fog caused by COVID-19 - New Atlas - November 27th, 2023
- The genes that made us truly human may also make us ill - BBC.com - November 25th, 2023
- Therapy to treat rare, hereditary diseases: Study - Hindustan Times - November 25th, 2023
- How the growth of a giant single cell is intertwined with daily self-rhythms - Phys.org - November 25th, 2023
- On this day: Mahmoud Abbas becomes leader of Fatah in 2004 - In-Cyprus - November 25th, 2023
- Evaluation of A-ring hydroxymethylene-amino- triterpenoids as ... - Nature.com - November 25th, 2023
- Disruption of the autism gene and chromatin regulator KDM5A alters ... - Science - November 23rd, 2023
- Scientists Created a Monkey With Two Different Sets of DNA - Smithsonian Magazine - November 23rd, 2023
- Genomic tug of war could boost cancer therapy - Science Daily - November 23rd, 2023
- What are stem cells? Throw light on various types of stem cells and ... - Insights IAS - November 23rd, 2023
- The Paul G. Allen Family Foundation awards $10.5 million to new ... - EurekAlert - November 23rd, 2023
- Daily briefing: Why these PhD scientists went into teaching - Nature.com - November 23rd, 2023
- Innovative Therapy Targets Rare, Hereditary Diseases - Mirage News - November 23rd, 2023
- Scientists uncover "genomic tug of war" that influences ... - News-Medical.Net - November 21st, 2023
- DOT1L is a barrier to histone acetylation during reprogramming to ... - Science - November 21st, 2023
- Tumor microenvironment composition & related therapy in HCC | JHC - Dove Medical Press - November 21st, 2023
- T-Therapeutics raises $59M in series A for T-cell receptors - BioWorld Online - November 19th, 2023
- A $3bn bet on finding the fountain of youth | Mint - Mint - November 19th, 2023
- A better way to study Parkinson's disease in the lab could lead to ... - EurekAlert - November 17th, 2023
Recent Comments